Article révisé par les pairs
Titre:
  • Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): A phase 3, double-blind randomised trial
Auteur:Tannock, Ian I.F.; Fizazi, Karim; Ivanov, Sergey; Karlsson, Camilla Thellenberg; Fléchon, Aude; Skoneczna, Iwona; Orlandi, Francisco; Gravis, Gwenaelle; Matveev, Vsevolod; Bavbek, Sevil; Gil, Thierry; Viana, Luciano; Arén, Osvaldo; Karyakin, Oleg; Elliott, Tony; Birtle, Alison; Magherini, Emmanuelle; Hatteville, Laurence; Petrylak, Daniel; Tombal, Bertrand; Rosenthal, Mark
Informations sur la publication:Lancet oncology, 14, 8, page (760-768)
Statut de publication:Publié, 2013-07
Sujet CREF:Cancérologie
MeSH keywords:Adult
Aged
Aged, 80 and over
Androgen Antagonists -- therapeutic use
Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use
Double-Blind Method
Drug Administration Schedule
Drug Resistance, Neoplasm
Europe
Humans
Intention to Treat Analysis
Kaplan-Meier Estimate
Male
Middle Aged
North America
Orchiectomy
Prednisone -- administration & dosage
Proportional Hazards Models
Prostatic Neoplasms -- drug therapy -- mortality -- secondary
Receptors, Vascular Endothelial Growth Factor -- administration & dosage
Recombinant Fusion Proteins -- administration & dosage
South America
Taxoids -- administration & dosage
Time Factors
Treatment Outcome
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1470-2045
info:doi/10.1016/S1470-2045(13)70184-0
info:pii/S1470204513701840
info:scp/84879786803
info:pmid/23742877

Documents en relation

DI-fusion